|
Ayoxxa Biosystems (stylized in its logo as AYOXXA) is a biotechnology company founded in 2010 in Singapore, and headquartered in Germany.〔〔 The company is known for developing a next-generation protein chip capable of detecting at once hundreds of diseases (including markers for cancer, allergies, cardiovascular or infectious diseases) from a small biological sample. The protein chip yields large amounts of data, being primarily aimed for use in biomedical research in academia and industry.〔〔〔〔〔 ==History== In 2006 the basic technology of an In-situ Encoded Bead-based Arrays (IEBA) multiplex protein chip began to be developed in the research labs of the Department of Bioengineering, at the National University of Singapore (NUS).〔〔〔 The project was led by Dieter Trau, Assistant Professor at NUS' Department of Bioengineering and Department of Chemical and Biomolecular Engineering,〔〔〔〔 As a result, and with the continued support of NUS, the start-up Ayoxxa Living Health Technologies Pte. Ltd was founded in 2010.〔〔〔 The rights to the intellectual property developed at NUS were exclusively licensed to Ayoxxa, for the company to further develop.〔 In 2012 the company expanded operations to Europe, establishing its headquarters in Cologne, Germany, as Ayoxxa Biosystems GmbH.〔 The company now conducts commercialization and further research from its headquarters, led by Andreas Schmidt as CEO and Co-founder.〔〔〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ayoxxa Biosystems」の詳細全文を読む スポンサード リンク
|